Here, we report a preclinical study of farletuzumab ecteribulin (MORAb-202, FZEC), a novel antibody-drug conjugate (ADC) targeting folate receptor alpha (FRα), using a panel of EC-PDX models with different molecular subtypes….Antitumour activity was observed across all four molecular subtypes. Tumor shrinkage was associated with FRα expression in FZEC 5 mg/kg group, whereas an overall FRA-independent tumor shrinkage was observed in FZEC 12.5 mg/kg and eribulin 3.2 mg/kg groups....These results suggest that FZEC may be a promising treatment for FRα-expressing EC of all four molecular subtypes.